On a relative basis, the stock has outperformed the S&P 500 by 5.14% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.31% in the last 1 week, and is up 3.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 0.66% and the 50-Day Moving Average is 2.32%.The 200 Day SMA reached 13.38% Quintiles Transnational Holdings Inc. is up 21.94% in the last 3-month period. Year-to-Date the stock performance stands at 12.6%.
Quintiles Transitional Holdings (Q) : 10 investment research analysts covering Quintiles Transitional Holdings (Q) have an average price target of $81.4 for the near short term. The highest target price given by the Brokerage Firm to the stock is $88 and the lowest target is $73 for the short term. Analysts expect the variance to be within $4.79 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Quintiles Transitional Holdings (NYSE:Q): stock was range-bound between the intraday low of $77.06 and the intraday high of $77.89 after having opened at $77.65 on Fridays session. The stock finally closed in the red at $77.65, a loss of -0.69%. The stock remained in the red for the whole trading day. The total traded volume was 1,251,626 shares. The stock failed to cross $77.89 in Fridays trading. The stocks closing price on Thursday was $77.31.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.